Placental Alkaline Phosphatase Antibody [ALPP/870] | 33-364

Placental Alkaline Phosphatase Antibody [ALPP/870] | 33-364 | Gentaur UK, US & Europe Distribution

Host: Mouse

Reactivity: Human

Homology: N/A

Immunogen: Recombinant full-length human ALPP protein was used as the immunogen for the placental Alkaline Phosphatase antibody.

Research Area: Cancer, Cell Cycle, Immunology

Tested Application: Flow, IF, IHC-P

Application: Flow Cytometry: 0.5-1 ug/million cells in 0.1ml
Immunofluorescence: 0.5-1 ug/ml
Immunohistochemistry (FFPE) : 0.25-0.5 ug/ml for 30 min at RT (1)
Prediluted format : incubate for 30 min at RT (2)
Optimal dilution of the placental Alkaline Phosphatase antibody should be determined by the researcher.

1. No special pretreatment is required for the immunohistochemical staining of formalin-fixed tissues.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required) , drip mAb solution onto the tissue section and incubate at RT for 30 min.

Specificiy: N/A

Positive Control 1: N/A

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: N/A

Validation: N/A

Isoform: N/A

Purification: Protein G affinity chromatography

Clonality: Monoclonal

Clone: ALPP/870

Isotype: IgG2b, kappa

Conjugate: Unconjugated

Physical State: Liquid

Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide

Concentration: 0.2 mg/mL

Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.

Alternate Name: Alkaline phosphatase, placental type, Alkaline phosphatase Regan isozyme, Placental alkaline phosphatase 1, PLAP-1, ALPP, PLAP

User Note: Optimal dilutions for each application to be determined by the researcher

BACKGROUND: Reacts with a 70kDa membrane-bound isozyme (Regan and Nagao type) of placental Alkaline Phosphatase (PLAP) occurring in the placenta during the 3rd trimester of gestation. It is highly specific for PLAP and shows no cross-reaction with other isozymes of alkaline phosphatase. Anti-PLAP reacts with germ cell tumors and can discriminate between these and other neoplasms. Somatic neoplasms e.g. breast, gastrointestinal, prostatic, and urinary cancers may also immunoreact with antibodies to PLAP. Anti-PLAP positivity in conjunction with anti-keratin negativity favors seminoma over carcinoma. Germ cell tumors are usually anti-keratin positive, but they regularly fail to stain with anti-EMA, whereas most carcinomas stain with anti-EMA. Anti-PLAP has been useful in the diagnosis of gestational trophoblastic disease.